DE69716414D1 - Benzoxazine zur erhöhung der synaptischen reaktionen - Google Patents

Benzoxazine zur erhöhung der synaptischen reaktionen

Info

Publication number
DE69716414D1
DE69716414D1 DE69716414T DE69716414T DE69716414D1 DE 69716414 D1 DE69716414 D1 DE 69716414D1 DE 69716414 T DE69716414 T DE 69716414T DE 69716414 T DE69716414 T DE 69716414T DE 69716414 D1 DE69716414 D1 DE 69716414D1
Authority
DE
Germany
Prior art keywords
compounds
subjects
ampa receptors
benzoxazine
reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716414T
Other languages
English (en)
Other versions
DE69716414T2 (de
Inventor
A Rogers
S Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69716414D1 publication Critical patent/DE69716414D1/de
Publication of DE69716414T2 publication Critical patent/DE69716414T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69716414T 1996-04-03 1997-03-28 Benzoxazine zur erhöhung der synaptischen reaktionen Expired - Lifetime DE69716414T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/624,335 US5736543A (en) 1996-04-03 1996-04-03 Benzoxazines for enhancing synaptic response
PCT/US1997/005184 WO1997036907A1 (en) 1996-04-03 1997-03-28 Benzoxazines for enhancing synaptic response

Publications (2)

Publication Number Publication Date
DE69716414D1 true DE69716414D1 (de) 2002-11-21
DE69716414T2 DE69716414T2 (de) 2003-06-12

Family

ID=24501596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716414T Expired - Lifetime DE69716414T2 (de) 1996-04-03 1997-03-28 Benzoxazine zur erhöhung der synaptischen reaktionen

Country Status (10)

Country Link
US (2) US5736543A (de)
EP (1) EP0891365B1 (de)
JP (1) JP3170294B2 (de)
AT (1) ATE226206T1 (de)
AU (1) AU708212B2 (de)
DE (1) DE69716414T2 (de)
DK (1) DK0891365T3 (de)
ES (1) ES2185932T3 (de)
NZ (1) NZ331992A (de)
WO (1) WO1997036907A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721936B2 (en) * 1996-04-03 2000-07-20 Regents Of The University Of California, The Benzoxazines for enhancing synaptic response
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
ES2258825T3 (es) * 1997-10-27 2006-09-01 Cortex Pharmaceuticals, Inc. Tratamiento de la esquizofrenia con ampakinas y neurolepticos.
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6011991A (en) * 1998-12-07 2000-01-04 Technology Patents, Llc Communication system and method including brain wave analysis and/or use of brain activity
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US7345036B2 (en) * 2001-06-14 2008-03-18 N.V. Organon (Pyrido/thieno)—[f]—oxazepine-5-one derivatives
GEP20063859B (en) * 2001-11-26 2006-06-26 Cortex Pharma Inc Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
EP1546235B1 (de) 2002-09-09 2021-10-20 Nektar Therapeutics Wasserlösliche polymer alkanale
NZ540468A (en) 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
EA200900937A1 (ru) * 2007-01-03 2009-12-30 Кортекс Фармасеутикалс, Инк. Соединения 3-замещенного-[1,2,3]бензотриазинона для усиления глутаматергических синаптических ответов
RS52108B (en) * 2007-01-03 2012-08-31 Les Laboratoires Servier 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US20100069377A1 (en) * 2007-03-23 2010-03-18 The Regents Of The University Of California Treatment of female sexual dysfunction by compounds that positively modulate ampa-type glutamate receptors
EP2154970B1 (de) 2007-05-17 2017-10-25 RespireRx Pharmaceuticals Inc. Disubstituierte amide zur verbesserung der glutamatergischen synaptischen reaktion
US8263591B2 (en) * 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
EP2948135B1 (de) 2013-01-25 2019-01-02 Case Western Reserve University Zusammensetzungen und verfahren zur behandlung von erkrankungen mit pervasiver entwicklung
AU2014277952A1 (en) 2013-06-13 2016-01-28 Veroscience Llc Compositions and methods for treating metabolic disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途
EP3684463A4 (de) 2017-09-19 2021-06-23 Neuroenhancement Lab, LLC Verfahren und vorrichtung für neuro-enhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3731749A4 (de) 2017-12-31 2022-07-27 Neuroenhancement Lab, LLC System und verfahren zur neuroverstärkung zur verbesserung der emotionalen reaktion
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CA3112564A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257396A (en) * 1962-06-11 1966-06-21 Geigy Chem Corp Certain 1, 3-benzoxazinone derivatives
DK0651746T3 (da) * 1992-07-24 2002-07-29 Univ California Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorer
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response

Also Published As

Publication number Publication date
WO1997036907A1 (en) 1997-10-09
DK0891365T3 (da) 2003-02-10
ATE226206T1 (de) 2002-11-15
US5736543A (en) 1998-04-07
AU2427497A (en) 1997-10-22
AU708212B2 (en) 1999-07-29
NZ331992A (en) 1999-02-25
DE69716414T2 (de) 2003-06-12
ES2185932T3 (es) 2003-05-01
EP0891365A1 (de) 1999-01-20
JP2000503664A (ja) 2000-03-28
JP3170294B2 (ja) 2001-05-28
US5962447A (en) 1999-10-05
EP0891365B1 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
DE69716414T2 (de) Benzoxazine zur erhöhung der synaptischen reaktionen
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
CA2138533A1 (en) Drugs that enhance synaptic responses mediated by ampa receptors
IL136783A0 (en) Benzoxazine compounds for enhancing synaptic response
DK1355669T3 (da) Forbedret kognitiv træning
DE69834590D1 (de) Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten
DE69910552D1 (de) Acylbenzoxazine zur erhöhung der synaptischen reaktion(en)
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted